Valuation: Isofol Medical AB

Market Cap 265M 27.44M 24.01M 22.13M 20.51M 38.94M 2.6B 39.57M 103M 1.29B 103M 101M 4.44B P/E 2026 *
-4.36x
P/E 2027 * -27.6x
Enterprise Value 163M 16.89M 14.78M 13.62M 12.63M 23.97M 1.6B 24.36M 63.53M 791M 63.42M 62.05M 2.73B EV / Sales 2026 *
-
EV / Sales 2027 * 4.02x
Free-Float
90.89%
Yield 2026 *
-
Yield 2027 * -
1 day+0.24%
1 week+12.77%
Current month+12.77%
1 month+16.57%
3 months+28.28%
6 months+16.08%
Current year+13.85%
1 week 0.73
Extreme 0.73
0.87
1 month 0.68
Extreme 0.675
0.87
Current year 0.55
Extreme 0.5515
0.99
1 year 0.55
Extreme 0.5515
1.18
3 years 0.45
Extreme 0.45
4.88
5 years 0.45
Extreme 0.45
14.44
10 years 0.45
Extreme 0.45
33.5
Manager TitleAgeSince
Chief Executive Officer 74 2024-01-08
Director of Finance/CFO 60 2024-08-12
Chief Executive Officer 61 2023-06-21
Director TitleAgeSince
Chairman 85 2010-06-30
Director/Board Member 76 2017-12-31
Director/Board Member 78 2024-01-03
Date Insider Type Main position Quantity % Market Cap.
21-12-09Sell 58,767 0.0364%
21-12-09Sell 58,767 0.0364%
21-06-13
Healthcom GmbH
BuyCompany 233,336 0.2239%
Change 5-day change 1-year change 3-year change Capi.($)
+0.24%+12.77%-3.71%+49.82% 27.48M
+1.36%+0.49%+59.62%+18.47% 313B
-0.74%-3.47%+29.63%-3.24% 70.89B
+0.87%+3.94%+50.04%+122.15% 9.58B
-0.77%+5.32%+8.02%+2.40% 8.82B
-5.65%+0.56%+11.76%+23.41% 4.25B
+1.07%-6.81%-7.11%+9.27% 4.29B
+1.01%-4.74%-33.99%+27.27% 3.39B
+0.98%+3.81%+53.51%+62.89% 2.74B
-2.91%-1.09%+13.77%-21.96% 2.22B
Average -0.44%+2.11%+18.15%+29.05% 41.93B
Weighted average by Cap. +0.86%+2.29%+51.04%+16.94%

Financials

2026 *2027 *
Net sales - 43.33M 4.48M 3.92M 3.61M 3.35M 6.36M 425M 6.46M 16.85M 210M 16.82M 16.46M 725M
Net income -61.25M -6.33M -5.54M -5.11M -4.73M -8.99M -601M -9.13M -23.82M -297M -23.78M -23.26M -1.03B -40.15M -4.15M -3.63M -3.35M -3.1M -5.89M -394M -5.99M -15.61M -194M -15.59M -15.25M -672M
Net Debt -102M -10.55M -9.23M -8.51M -7.88M -14.97M -1B -15.21M -39.67M -494M -39.6M -38.74M -1.71B -91M -9.41M -8.23M -7.59M -7.03M -13.35M -893M -13.57M -35.39M -441M -35.33M -34.56M -1.52B
Logo Isofol Medical AB
Isofol Medical AB is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
Employees
6
Date Price Change Volume
26-07-07 SEK 0.8300 +0.24% 1,075,219
26-07-06 SEK 0.8280 +2.22% 952,753
26-07-03 SEK 0.8100 +5.88% 1,394,039
26-07-02 SEK 0.7650 +1.32% 679,514
26-07-01 SEK 0.7550 +2.58% 96,649
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISOFOL Stock